Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8436185 | JANSSEN BIOTECH | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(4 years from now) | |
US8071623 | JANSSEN BIOTECH | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(6 years from now) | |
US11673877 | JANSSEN BIOTECH | Niraparib compositions |
Mar, 2038
(13 years from now) | |
US11091459 | JANSSEN BIOTECH | Niraparib compositions |
Mar, 2038
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8143241 | JANSSEN BIOTECH | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
US8071579 | JANSSEN BIOTECH | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
US8859562 | JANSSEN BIOTECH | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
US11207311 | JANSSEN BIOTECH | Method of treating prostate cancer |
Jul, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(6 years from now) | |
US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(10 years from now) | |
US11684620 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(11 years from now) | |
US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(11 years from now) | |
US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(2 years from now) | |
US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(6 years from now) | |
US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(2 years from now) | |
US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(2 years from now) | |
US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
USRE49353 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
US10702508 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Apr, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-808) | Sep 17, 2022 |
New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment of non-metas...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5604213 | JANSSEN BIOTECH | 17-substituted steroids useful in cancer treatment |
Feb, 2014
(10 years ago) | |
US8822438 | JANSSEN BIOTECH | Methods and compositions for treating cancer |
Aug, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-765) | Feb 07, 2021 |
New Indication(I-663) | Dec 10, 2015 |
New Chemical Entity Exclusivity(NCE) | Apr 28, 2016 |
Drugs and Companies using ABIRATERONE ACETATE ingredient
NCE-1 date: 29 April, 2015
Market Authorisation Date: 28 April, 2011
Treatment: Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel; Use in combination with...
Dosage: TABLET;ORAL